References
- Smith CL, O'Malley BW. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 2004;25:45–71.
- Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. a report of the International Tibolone Consensus Group. Maturitas 2005;51:21–28.
- Archer DF, Hendrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, Den Hollander W, Stathopoulos V, Helmond FA For the tibolone histology of the endometrium and breast endpoints (THEBES) study group. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911–918.
- Hammar M, van de Weijer P, Franke H, Pornel B, von Mauw E, Nijland E; on behalf of the TOTAL Study Investigators Group. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 2007;114:1522–1529.
- Nijland EA, Weijmar Schultz WCM, Nathorst-Böös J, Helmond FA, van Lunsen RHW, Palacios S, Norman RJ, Mulder RJ, Davis SR; for the LISA Study Investigators. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646–656.
- Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee D, Seifert W, Eastell R; for the LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. NEJM 2008;359:21–32.
- Opatrny L, Dell'Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008;115:169–175.
- Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz, B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van OS S, Beckmann MW; on behalf of the LIBERATE Study Group. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised non-inferiority trial. Lancet Oncol 2009;10:135–146.